Orchard Therapeutics raises $150m in Series C funding to advance gene therapies for rare diseases
Orchard Therapeutics, a leader in gene therapy specializing in rare diseases, has successfully secured $150 million through a Series C funding round. This substantial capital ... Read More
GlaxoSmithKline transfers rare disease gene therapy portfolio to Orchard Therapeutics in strategic deal
GlaxoSmithKline (GSK), a leading British pharmaceutical company, has entered into a significant agreement with Orchard Therapeutics, transferring its rare disease gene therapy drugs in exchange ... Read More